Phase I trial

TOKYO, Japan, June 2026 Heartseed Inc. announced the successful treatment of the first patient in its Phase I/II EMERALD...

SHANGHAI and HONG KONG, China, June 10, 2026 Antengene announced that China’s National Medical Products Administration (NMPA) has approved...

CARY, N.C. and BRADENTON, Fla., May 20, 2026 Continuity Biosciences has announced the initiation of a Phase I first-in-human...

SAN FRANCISCO, May 6, 2026 Artera announced that the U.S. Food and Drug Administration (FDA) has granted clearance for...

SUZHOU, China, May 6, 2026 SiranBio announced a major global licensing agreement with GSK for its investigational siRNA therapeutic...

STOCKHOLM, Sweden – May 6, 2026 Spago Nanomedical AB (publ) has announced that its ongoing Phase I/IIa Tumorad-01 study...

SHANGHAI, April 10, 2026 Shanghai Ark Biopharmaceutical Co., Ltd. has announced a key clinical milestone with the successful dosing...

Cambridge, Massachusetts, USA / Rotterdam, Netherlands / Shanghai, China | March 22, 2026 Harbour BioMed has announced the online...